Macrophages are important immune effector cells in various inflammatory diseases. They respond efficiently to danger signals by phagocytosis and secretion of inflammatory eicosanoids and cytokines to recruit and activate immune cells (1) . Eicosanoids are a class of oxygenated hydrophobic compounds that largely function as paracrine mediators. Metabolism of arachidonic acid (AA) leads to several families of lipid mediators collectively known as eicosanoids, including prostaglandins (PGs), thromboxane, leukotrienes (LTs), and lipoxins, along 2 major metabolic pathways, the lipoxygenase (LOX) and the cyclooxygenase (COX) pathways. Eicosanoids possess potent biological activities and are involved in maintenance of normal hemostasis, regulation of blood pressure, renal function, and reproduction, as well as host defense (2) .
Phospholipase A 2 , in particular group IV cytosolic phospholipase A 2 (cPLA 2 ), mediates agonist-induced AA release, which is the rate-limiting step in the biosynthesis of eicosanoids (3) . Activation of cPLA 2 requires phosphorylation by p38 MAPK and an increase in intracellular calcium (4, 5) . 5-LOX catalyzes oxygenation of AA, resulting in LT biosynthesis. 5-LOX activity is regulated by several factors, including intracellular Ca 2ϩ , translocation of 5-LOX from the cytosol to the nuclear membrane, and phosphorylation of 5-LOX (6) . Alternatively, AA released by cPLA 2 is presented to COX and is then metabolized to an intermediate PG), PGH 2 , coupled with metabolism by downstream enzymes into PGs, prostacyclin, and thromboxane A 2 (7) . COX exists as 2 isoforms referred to as COX-1 and COX-2. COX-1 is expressed constitutively in most tissues whereas COX-2 is not detectable in most normal tissues or resting immune cells, but its expression can be induced by factors such as endotoxins, cytokines, growth factors, and carcinogens (8) .
Mammals express a variety of small, amphipathic antimicrobial peptides including defensins and cathelicidins. The only endogenous cathelicidin in humans, LL-37/hCAP-18, is expressed by various cell types, such as epithelial cells (9, 10) , keratinocytes (11) , and specific leukocytes (12) . It is also present at high concentrations as the inactive proform hCAP-18 in the secondary granules of neutrophils (13, 14) . Once hCAP18 is secreted from neutrophils, it is processed into the active LL-37 peptide by proteinase 3 that is present in the primary granules of neutrophils (15) . Besides a broad range of direct antimicrobial activities, LL-37 also exhibits functions important for immune responses, which are mediated by several different receptors. For example, LL-37 induces angiogenesis (16) and serves as a chemoattractant for neutrophils, monocytes, T cells, and progenitor cells via FPR2/ALX (17, 18) . In addition, LL-37 promotes IL-1␤ processing and release by activating the P2X 7 receptor (P2X 7 R; ref. 19 ) and induces keratinocyte migration via transactivation of epithelial growth factor receptor (EGFR; ref. 20) .
In the present study, we show that LL-37 promotes LTB 4 and thromboxane A 2 (TXA 2 ) production by human monocyte-derived macrophages (HMDMs) via temporally and mechanistically distinct actions, suggesting that these 2 eicosanoids play separate roles in inflammatory responses elicited by macrophages. Finally, we demonstrate that the LL-37-eicosanoid signaling pathway indeed occurs during inflammatory responses in vivo.
MATERIALS AND METHODS

Reagents
Polyclonal antibodies against cPLA 2 , phosphorylated cPLA 2 , phosphorylated ERK1/2, phosphorylated p38, and COX-2 were from Cell Signaling Technology (Danvers, MA, USA). The antibodies against COX-1 and thromboxane synthase (TXAS) were purchased from Cayman Chemical (Ann Arbor, MI, USA). Human 5-LOX antiserum was a kind gift from Dr. Olof Rådmark (Karolinska Institutet, Stockholm, Sweden). RPMI 1640 cell culture medium, HEPES, phosphatase inhibitor cocktail, aspirin, SC-650, Celecoxib, KN-62, N-tosyl-lphenylalanine chloromethyl ketone (TPCK), RIPA lysis buffer, and monoclonal anti-␣-tubulin antibody were from Sigma-Aldrich (St. Louis, MO, USA). Fetal bovine serum (FBS), macrophage colony-stimulating factor (M-CSF), fura-2 acetoxymethyl ester (FURA-2AM), and Heochst were from Life Technologies (Paisley, UK). U0126 and SB203580 were from Tocris Bioscience (Bristol, UK). Synthetic LL-37 (NH 2 -LLGDFFRKSKEKIGKEFKRIVQRIKDFFRNLVPRTES-COOH), sequence-scrambled LL-37 (NH 2 -GLKLRFEFSKIKGEFLKTPEVR-FRDIKLKDNRISVQR-COOH), cathelicidin-related antimicrobial peptide (mCRAMP; NH 2 -GLLRKGGEKIGEKLKKIGQKI-KNFFQKLVPQPEQ-COOH), WKYMVm, WRW4 peptides, and pannexin-1 (Panx-1) antagonist peptide 10 Panx (WRQAAFVDSY) were from Innovagen (Lund, Sweden). Recombinant murine TNF-␣ was purchased from PeproTech (Rocky Hill, NJ, USA).
Cell culture
Human mononuclear cells were isolated from freshly prepared buffy coats (Karolinska Hospital Blood Bank, Stockholm, Sweden) by Ficoll-Paque Premium (GE Healthcare Bio-Sciences, Uppsala, Sweden) gradient centrifugation. Differentiation of human monocytes to macrophages was achieved by plating mononuclear cells in cell culture plates for 2 h, and then unbound cells were washed away with PBS, followed by cell culture over 7 d in RPMI 1640 supplemented with 10% FBS (heat-inactivated), 25 mM HEPES, penicillin (100 U/ml), streptomycin (100 g/ml), and M-CSF (50 ng/ml).
RNA extraction and quantitative real-time PCR
Extraction of total RNA was performed with the RNA Mini kit (Bioline, London, UK) including an on-column DNase digestion step. RNA concentration and quality were assessed by Nanodrop (Thermo Scientific, Wilmington, DE, USA). cDNA was synthesized from total RNA by SuperScript II reverse transcriptase (Life Technologies), and real-time PCR was performed in a TaqMan 7300 instrument (Life Technologies). Normalizations were made to ␤-actin. The primer/ probe pairs were obtained by Assay-on-Demand (Life Technologies).
Western blot analysis
After treatments, HMDMs were lysed with RIPA buffer together with a complete protease inhibitor cocktail (Roche Diagnostics, Mannheim, Germany) and phosphatase inhibitor cocktail. The SDS-PAGE and Western blot analysis were carried out as described previously (21) .
Analysis of biosynthesis of AA-derived lipids by enzyme immunoassay
The levels of leukotrienes and prostanoids were determined with enzyme immunoassay (Cayman Chemical), according to the manufacturer's instructions. Formation of TXA 2 was also assessed by LC-MS and GC-MS analysis, essentially as described previously (22, 23) .
Intracellular calcium mobilization
HMDMs were cultured and differentiated as described above. Measurements of intracellular calcium were carried out with fluorescence spectroscopy using FURA2-AM, essentially as described previously (21) . Briefly, the cells were incubated in medium containing 4 M FURA-2AM plus 2.5 mM probene-cid or medium with 2.5 mM probenecid for 60 min in 5% CO 2 at 37°C. Cells were then washed 4 times with a buffer solution (135 mM NaCl, 4.6 mM KCl, 1.2 mM MgCl 2 , 1.5 mM CaCl 2 , 11 mM glucose, and 10 mM HEPES, pH 7.4), and 50 l of buffer was added to each well. The plates were transferred to a fluorometer (Fluostar; BMG Technologies, Ortenburg, Germany), and 50 l of different reagents or buffer solution (control) was injected into individual wells, and the cells were monitored for 120 s. Control wells containing cells that had not been exposed to FURA-2AM were used to subtract background autofluorescence. The results are given as the ratio of mean fluorescence intensities at 340 and 380 nm.
5-LOX translocation detected by immunohistochemistry
Human primary macrophages were cultured in Lab Tek II chamber slides (Thermo Fisher Scientific, Rochester, NY, USA). After incubation with 20 g/ml of LL-37 for 30 min, cells were washed 3 times with PBS, followed by fixation with 2% paraformaldehyde (PFA) for 10 min and permeabilization with a mixture of 0.1% sodium citrate and 0.1% Triton X-100 for 5 min at room temperature. After preincubation with 10% goat serum for 30 min, cells were incubated with human 5-LOX antiserum at 4°C overnight. The cells were then rinsed and incubated with Cy3-conjugated goat antirabbit-IgG (Jackson ImmunoResearch, West Grove, PA, USA) at room temperature for 30 min. After being stained, the slides were mounted using an antifading mounting medium (Vector Laboratories, Burlingame, CA, USA) and imaged with a confocal microscope (Olympus FV1000; Olympus Corp., Tokyo, Japan).
Live image
HMDMs were cultured and differentiated in glass-bottomed microwell dishes (MatTek Corp., Ashland, MA, USA) for 7 d. After being washed with PBS, FITC-conjugated LL-37 (10 g/ml) was added into the dishes and incubated at 37°C for 15 min, and then Heochst (0.5 g/ml) was added for nuclear staining. After 5 min, the fluorescence in live cells was visualized by confocal microscopy (Olympus FV1000).
Flow cytometric analysis
HMDMs were preincubated with endocytosis inhibitors for 1 h at 37°C, afterward 10 g/ml of FAM-conjugated LL-37 was added and incubated for another 1 h. After being washed with PBS for 3 times, the cells were collected and the fluorescence intensity of the cells was measured using a FACSort (BD Biosciences, Franklin Lakes, NJ, USA) and analyzed using BD Cellquest software (BD Biosciences).
Animals
Wild-type (WT) male C57BL/6 mice and male cathelicidindeficient (Cnlp Ϫ/Ϫ ) mice on a C57BL/6 background were kept in animal housing with constant temperature and humidity, 12 h light-dark cycles, and ad libitum food and water. Cnlp Ϫ/Ϫ mice are deficient in CRAMP, the murine orthologue of LL-37. The original phenotype of Cnlp Ϫ/Ϫ mice has been described previously (24) . All experiments were approved by the Regional Ethical Committee for Animal Experimentation.
Intraperitoneal injection
In the first experiment, WT male C57BL/6 mice were intraperitoneally injected with 100 l of PBS, mouse TNF-␣ (mTNF␣, 50 ng/mouse), or mCRAMP (10 g/mouse). In the second experiment, WT and Cnlp Ϫ/Ϫ male C57BL/6 mice were intraperitoneally injected with 100 l mTNF␣ (50 ng/mouse). After 4 h, the peritoneal cavity was lavaged with 3 ml of PBS. The lavage fluid was centrifuged, and the resulting cell pellet was resuspended in PBS with 0.5% BSA and stained with anti-Gr-1 (Biolegend, San Diego, CA, USA) and anti-F4/80 (AbD Serotec, Düsseldorf, Germany) to discriminate between neutrophils, monocytes, and macrophages. Cell-surface molecule expression was assessed on a FACSort (BD Biosciences) and analyzed with BD Cellquest software to determine the percentage neutrophils (Gr-1 ϩ ) monocytes (Gr-1 ϩ and F4/80 ϩ ) and macrophages (F4/80 ϩ ) in the recruited cell population. The remaining supernatants were saved at Ϫ80°C for subsequent detection of LTB 4 and TXB 2 .
Statistical analysis
Results are presented as means Ϯ sd. Differences between the means were evaluated using 1-way ANOVA or Student's t test. A value of P Ͻ 0.05 was considered statistically significant.
RESULTS
LL-37 promotes the release of arachidonic acidderived lipid mediators from HMDMs in a time-and dose-dependent manner
The levels of LTB 4 , cysteinyl LTs (cysLT S ), PGI 2 (analyzed as 6-keto PGF 1␣ ), PGE 2 , and TXA 2 (analyzed as TXB 2 ) in the retrieved cell culture medium were measured after HMDMs were incubated with 20 g/ml of LL-37 for different time periods. We found that LL-37 enhances the production of TXB 2 , PGE 2 , and LTB 4 from HMDMs, while the concentrations of 6-keto PGF 1␣ and cysLTs remain unchanged (Fig. 1A) . Since HMDMs produced much higher amounts of TXB 2 than PGE 2 in response to LL-37 treatment, we next focused on LL-37-induced TXB 2 and LTB 4 production by HMDMs. Our results further show that LL-37-induced LTB 4 production from HMDMs peaked at ϳ1 h (Fig.  1B) , while TXB 2 production steadily increased and peaked at a late time point at ϳ6 -8 h (Fig. 1C) . Furthermore, LL-37 promoted LTB 4 and TXB 2 production of HMDMs in a dose-dependent manner; while sequence-scrambled LL-37 (sLL-37) did not evoke any significant responses (Fig. 1D, E) .
LL-37 induces intracellular calcium mobilization and activates ERK1/2 and p38 in human macrophages, resulting in cPLA 2 phosphorylation and 5-LOX translocation
Further studies demonstrated that LL-37 but not sLL-37 induced intracellular calcium mobilization in HMDMs ( Fig. 2A) . In addition, two MAPKs, ERK1/2 and p38, were activated in LL-37-treated HMDMs in a time-dependent manner (Fig. 2B) . Moreover, the specific ERK inhibitor U0126 totally abolished LL-37-induced LTB 4 production (Fig. 2C) . The potent p38 MAPK inhibitor SB203580 also partly suppressed LTB 4 production in LL-37-treated HMDMs (Fig. 2D) . Lastly, cPLA 2 and 5-LOX, 2 key enzymes responsible for LTB 4 production, were activated in LL-37-treated HMDMs. Thus, LL-37 induced cPLA 2 phosphorylation in a time-dependent manner (Fig. 2B) , and translocation of 5-LOX from cytosol into the nucleus was detected by confocal microscopy ( Fig. 2E and Supplemental Fig. S1 ), although the gene and protein expression of 5-LOX was not significantly altered in LL-37-treated HMDMs (Fig. 3A, B) . Moreover, our results showed that LL-37 (10 and 20 g/ml) had no effects on cell viability of HMDMs (Supplemental Fig.  S2 ), indicating that the LL-37-induced effects in our experimental settings were not due to cytotoxic activity of LL-37 on macrophages.
COX-1 and COX-2 are involved in LL-37-induced TXA 2 production by HMDMs with different temporal specificity
Additional experiments showed that LL-37 selectively upregulated the gene and protein expression of COX-2 in a time-dependent manner (Fig. 3A, B) . Moreover, the ERK MAPK inhibitor U0126 significantly suppressed LL-37-induced COX-2 gene expression (Fig. 3C ) and TXB 2 production at 6 h (Fig. 3D) . However, the p38 MAPK inhibitor SB203580 and NF-k B inhibitor TPCK exhibited no significant effects on LL-37-induced COX-2 gene expression and TXB 2 production, indicating that these responses are independent of p38 MAPK and NF-k B pathways ( Fig.  3C-E) . Interestingly, the COX inhibitor aspirin and selective COX-1 inhibitor SC-560, but not the specific COX-2 inhibitor celecoxib, completely abolished LL-37-induced TXB 2 production after 1 h (Fig. 3F) . In contrast, celecoxib completely inhibited LL-37-induced TXB 2 production by HMDMs at 6 h (Fig. 3G) , demonstrating that LL-37-induced TXB 2 production by HMDMs at late time ponts is mainly derived from COX-2. P2X 7 R is a candidate receptor involved in LL-37-induced early production of LTB 4 and TXA 2 Our finding that sLL-37 does not promote LTB 4 or TXB 2 production from HMDMs (Fig. 1D, E) indicates that LL-37-induced responses are mediated by specific receptor(s). Therefore, we tested several inhibitors of receptors known to transduce LL-37 signaling (the specific P2X 7 R inhibitor KN-62, FPR2/ALX antagonist WRW4, P2X receptor inhibitor suramin, GPCR inhibitor pertussis toxin, and EGFR inhibitor AG-1478). The specific P2X 7 R inhibitor KN-62 totally abolished LTB 4 production from LL-37-treated HMDMs at 1 h (Fig. 4A) , while the FPR2/ALX antagonist WRW4 had no effect (Fig. 4B) . KN-62 pretreatment also blocked LL-37-induced intracellular calcium mobilization (Fig. 4C) , as did a specific P2X 7 R antibody (Fig. 4D) . KN-62 also partly inhibited phosphorylation of ERK1/2 in LL-37-treated HMDMs (Fig. 4E) . Accordingly, WRW4 did not inhibit ERK1/2 phosphorylation in LL-37-treated HMDMs (Fig. 4E) . Surprisingly, KN-62 pretreatment had no effect on LL-37-induced TXB 2 production at 6 h Figure 1 . LL-37 promotes LTB 4 and TXB 2 production by HMDMs in a timeand dose-dependent manner. A) HMDMs were treated with 20 g/ml of LL-37 for 0 -24 h, and the concentrations of LTB 4 , CysLTs, PGI 2 (6-keto PGF 1␣ ) PGE 2 , and TXA 2 (TXB 2 ) were analyzed in the medium. Depicted results are representative of Ն4 donors. B, C) In a separate experiment, the time courses for release of LTB 4 (nϭ6; B) and TXB 2 (nϭ6; C) were determined. D, E) HMDMs were treated with 0, 5, 10, 15, and 30 g/ml of LL-37 or sequence-scrambled LL-37 (sLL-37) for 1 or 6 h, and the concentrations of LTB 4 (nϭ3; D) or TXB 2 (nϭ4; E) were detected. NS, no significance. *P Ͻ 0.05, **P Ͻ 0.01, ***P Ͻ 0.001. (Fig. 4G) or LL-37-induced up-regulation of COX-2 gene expression at 4 h (Fig. 4H) , although it totally abolished LL-37-induced TXB 2 production at 1 h (Fig.  4F) . We also tested WRW4, suramin, pertussis toxin, and AG-1478, but none of them exhibited inhibitory effects on LL-37-induced COX-2 expression or TXB 2 production at late time points (Supplemental Fig. S3 ).
It has been reported that Panx-1 is a component of the P2X 7 R signaling pathways and Panx1 channels can be activated by prolonged stimulation of P2X 7 R (25). However, blocking of Panx-1 by a specific antagonist, viz. peptide 10 Panx, did not show any inhibitory effects on LL-37-induced LTB 4 release at 1 h (Fig. 4I) or TXB 2 production 6 h (Fig. 4J) . , blue trace; sLL-37 (20 g/ ml); red trace; or buffer, green trace. Intracellular calcium mobilization was measured and calculated as described in Materials and Methods. B) HMDMs were treated with LL-37 (20 g/ml) for 0 -60 min, and phosphorylation of ERK, p38, and cPLA 2 was detected by Western blots (representative results from 3 donors). C, D) HMDMs were pretreated with the ERK MAPK inhibitor U0126 (1 M, nϭ4; C) or the p38 MAPK inhibitor SB203580 (1 M, nϭ3; D) for 1 h, followed by incubation with 20 g/ml of LL-37 for another 1 h. LTB 4 in the culture medium was measured by EIA. E) HMDMs were treated with LL-37 (20 g/ml) for 30 min and translocation of 5-LOX was detected by immunohistochemistry and visualized by confocal microscopy (red: 5-LOX; blue: DAPI). Picture is representative of 3 donors. **P Ͻ 0.01, ***P Ͻ 0.001.
Internalization of LL-37 by HMDMs contributes to LL-37-induced late COX-2 activation and TXA 2 production
Next, we searched for the molecular process that is responsible for LL-37-induced COX-2 expression and TXB 2 production at late time points. Intriguingly, we found that LL-37 was internalized by HMDMs and located in the cytosolic compartment (Fig. 5A, B, cf. Supplemental Video S1). Two inhibitors of endocytosis, cytochalasin B and dynasore, significantly , nϭ4) , the p38 MAPK inhibitor SB203580 (1 M, nϭ4) , and the NF-kB inhibitor TPCK (1 M, nϭ4) for 1 h, followed by incubation with 20 g/ml of LL-37 for 4 h. COX-2 gene expression was measured as described in Materials and Methods. D, E) HMDMs were pretreated with U0126 (1 M, nϭ6) or SB203580 (1 M, nϭ6; D) , or TPCK (1 M, nϭ4; E) for 1 h and then treated with LL-37 (20 g/ml; 6 h). TXB 2 in the medium was measured by EIA. F, G) HMDMs were pretreated with a COX-1-specific inhibitor SC-560 (1 M), the COX-2 selective celecoxib (1 M), or aspirin (ASA, 1 M) for 1 h before LL-37 challenge (20 g/ml) for 1 h (nϭ4; F) or 6 h (nϭ5; G). TXB 2 in the medium was measured by EIA. NS, no significance. *P Ͻ 0.05, **P Ͻ 0.01, ***P Ͻ 0.001. blocked LL-37 internalization by HMDMs (Fig. 5C ) as well as COX-2 induction (Fig. 5D, E) and TXB 2 production (Fig. 5F, G) at late time points, suggesting that COX-2 expression is enhanced via internalized LL-37.
LL-37 DRIVES EICOSANOID SYNTHESIS BY MACROPHAGES
Cathelicidin elicits LTB 4 and TXA 2 production in vivo
To find evidence for the involvement of cathelicidin in the production of eicosanoids in vivo, we designed 2 experiments. First, C57BL/6 WT mice were injected intraperitoneally with mCRAMP (mouse LL-37 orthologue), using PBS and mTNF␣ as negative and positive controls, respectively. Thus, injection of mCRAMP significantly enhanced levels of LTB 4 (Fig. 6A) and TXA 2 (Fig.  6B ) in mouse ascites. Meanwhile, the amount of leukocytes in ascites from mice injected with PBS was 2.14 Ϯ 0.87ϫ10 5 cells/ml (ϳ40% macrophages, ϳ37% neutrophils, and ϳ23% monocytes), and similar amounts and composition of cells were observed in ascites from mice injected with mCRAMP (2.14Ϯ0.77ϫ10 5 cells/ml, ϳ35% macrophages, ϳ37% neutrophils, and ϳ28% monocytes). In mice injected with mTNF␣, the total amount of cells and relative amounts of neutrophils were increased (3.94Ϯ1.24ϫ10 5 cells/ml, ϳ24% macrophages, ϳ50% neutrophils, and ϳ26% monocytes). In the second experiment, mTNF␣ was injected intraperitoneally into WT and Cnlp Ϫ/Ϫ mice. After 4 h, significantly less LTB 4 and TXB 2 were detected in mouse ascites from Cnlp Ϫ/Ϫ mice than WT mice (Fig. 6C, D) . Compared with WT mice (6.24Ϯ5.66ϫ10 5 cells/ml, ϳ40% macrophages, ϳ56% neutrophils, and ϳ4% monocytes), the total amount of C) or specific P2X 7 R antibody (D) and incubated for 1 h. Afterward, cells were washed 4 times, and 50 l of buffer was added to the corresponding wells. Subsequently, intracellular calcium mobilization was measured on addition of LL-37 (20 g/ml). E) HMDMs were pretreated with KN-62 (1 M) or WRW4 (1 M) for 1 h, incubated with LL-37 (20 g/ml) for 10 min, and washed with PBS for 3 times. Phosphorylation of ERK 1/2 was detected by Western blots. Images are representative of Ն3 experiments. F, G) HMDMs were pretreated with KN-62 (1 M) for 1 h, followed by incubation with LL-37 (20 g/ml) for 1 h (nϭ4; F) or 6 h (nϭ4; G) TXB 2 in the medium was measured by EIA. H) HMDMs were pretreated with KN-62 (1 M) for 1 h and incubated with LL-37 (20 g/ml) for 4 h (nϭ4). COX-2 gene expression was measured by real-time PCR. I, J) HMDMs were pretreated with Panx-1 antagonist peptide 10 Panx (200 M) for 1 h, followed by incubation with LL-37 (20 g/ml) for 1 h (I) or 6 h (J). The medium was collected, and concentrations of LTB 4 (nϭ3) and TXB 2 (nϭ4) were measured by EIA. NS, no significance. *P Ͻ 0.05, **P Ͻ 0.01, ***P Ͻ 0.001. cells and macrophages were slightly increased in ascites from Cnlp Ϫ/Ϫ mice (8.54Ϯ4.73ϫ10 5 cells/ml, ϳ52% macrophages, ϳ43% neutrophils, and ϳ5% monocytes).
DISCUSSION
Previous work has shown that various antimicrobial peptides, including LL-37, are released by human polymorphonuclear neutrophils, epithelial cells, and additional inflammatory cells during infection and certain inflammatory responses. The released peptides interact with the surrounding macrophages to enhance clearance of bacteria (26) , promote adhesion of classical monocytes (27) and regulate the production of inflammatory mediators in different cell types (28 -30) . Therefore, we attempted to investigate if LL-37 can regulate the production of eicosanoids by HMDMs. Results from initial LC-MS and GC-MS analyses indicated that the level of TXB 2 in the medium from LL-37-treated HMDMs was significantly elevated. This result was confirmed by screening the production of a series of AA-derived lipid mediators [LTB 4 , CysLTs, PGI 2 (as 6-keto PGF 1␣ ) PGE 2 , and TXA 2 (as TXB 2 )] by HMDMs treated with LL-37 for different time points and was found that the amounts of LTB 4 , TXA 2 , and PGE 2 released from HMDMs were significantly increased after treatment with LL-37.
COX-1 and COX-2 mediate LL-37-induced early and late TXB 2 production by HMDMs
Several lines of evidence indicate that the 2 COX isoforms can regulate different phases of prostanoid biosynthesis in activated cells (31) (32) (33) . In line with this notion, we found that intact HMDMs contain abundant COX-1 whereas COX-2 is expressed at low levels ( Fig.   Figure 5 . LL-37 internalization by human macrophages is associated with COX-2-derived TXB 2 production by LL-37-treated human macropohages. A) HMDMs were cultured and differentiated in glass-bottom microwell dishes for 7 d. FITC-conjugated LL-37 (10 g/ml) was added at 37°C for 30 min, and its location in live cells was observed by confocal microscopy (blue: nucleus, green: FITC-conjugated LL-37). Scale bar ϭ 10 M. B) HMDMs were incubated with FITC-conjugated LL-37 (10 g/ml) for 0 -4 h. Cells were collected, washed with PBS 3 times, and mean fluorescence intensity (MFI) of the cells was measured by FACS (nϭ3). C) HMDMs were pretreated with endocytosis inhibitors cytochalasin B (cytoB, 1 M) and dynasore (20 M) at 37°C for 1 h, followed by incubation with FITC-LL-37 (10 g/ml) for another 1 h. Cells were collected, washed 3 times with PBS, and MFI of the cells was measured by FACS (nϭ4). D, E) HMDMs were pretreated with cytoB (1 M, nϭ3; D) or dynasore (20 M, nϭ4; E) for 1 h, and then incubated with LL-37 (20 g/ml). After 4 h, cells were washed 3 times with PBS, followed by real-time PCR measurement of COX-2 mRNA. F, G) HMDMs were pretreated with cytoB (1 M, nϭ4; F) or dynasore (20 M, nϭ4; G) for 1 h, followed by incubation with 20 g/ml of LL-37. After 6 h, the culture medium was collected, and TXB 2 was measured by EIA. NS, no significance. **P Ͻ 0.01, ***P Ͻ 0.001. 3B). At early time points, before COX-2 expression is upregulated (ϳ1 h), free AA is metabolized by existing COX-1 and TXAS into TXA 2 . However, COX-2 expression is gradually elevated and both COX-1 and COX-2 exist in HMDMs at late time points (ϳ6 h). Although COX-2 appears to couple preferentially to PGE synthase or PGI 2 synthase in various cell types (7), our pharmacological data show that COX-2 couples to TXAS to produce TXA 2 in LL-37-stimulated HMDMs at late time points. 4 and TXB 2 production appears to be mediated via P2X 7 R
LL-37-induced early LTB
We next asked whether any of the previously described cell surface receptors for LL-37, viz. FPR2/ALX (16, 17) P2X 7 R, (19) , EGFR (20) , and CXCR2 (34) , are involved the biphasic profile of eicosanoid release from HMDMs. Since LL-37-induced LTB 4 production in human neutrophils is mediated via FPR2/ALX, we were surprised that our pharmacological data, as well as blocking effects of a P2X 7 R antibody, suggested that LL-37-induced early lipid production is signaled via P2X 7 R, rather than the expected FPR2/ALX (Fig. 4) . P2X 7 R is a ligand-gated ion channel and shows remarkable functional plasticity (35) . It has been reported that P2X 7 R is highly expressed by cells of the hemopoietic lineage and mediates cell death, killing of infectious organisms, and regulation of inflammatory responses (36) . In our hands, HMDMs also demonstrated high expression of P2X 7 R (Supplemental Fig. S4 ). We also ascertained that effects of LL-37 are not an indirect effect of the P2X 7 R ligand ATP or involve the channel protein Panx-1 that can be activated by prolonged stimulation of P2X 7 R (25) leading to formation of pore-like structures permeable to large organic mole- 
Internalization of LL-37 by HMDMs contributes to COX-2 up-regulation
We next used pharmacological tools to test whether TXA 2 production by HMDMs at late time points is receptor dependent. We could not demonstrate involvement of P2X 7 R, although it has been reported that this receptor signals LL-37-induced COX-2 expression and PGE 2 production in human gingival fibroblasts (38) . Furthermore, suramin (P2X), WRW4 (FPR2/ ALX), AG-1478 (EGF), and pertussis toxin (GPCR) all failed to affect LL-37-induced COX-2 expression and TXA 2 production (Supplemental Fig. S3 ). Instead, we found that LL-37, with time, was internalized by HMDMs, gradually localizing in the cytosolic compartment (Fig. 5A , B, and Supplemental Video S1). Interestingly, previous studies have also indicated that endocytosis of LL-37 is associated with several functional responses of the recipient cell. For example, in this way, LL-37 induced IL-8 expression in epithelial cells, stimulated maturation/ differentiation of human dendritic cells and monocytes, and changed adhesive properties of endothelial cells (10, 27, 39, 40) . However, in all these instances it was not clarified how internalized LL-37 couples to intracellular second messengers, in our case activated ERK MAPK, to elicit a biological response. A mechanistic model for LL-37-induced early and late eicosanoid generation in macrophages is presented in Fig. 7 .
Cathelicidin mCRAMP can regulate eicosanoid production in vivo
To determine whether LL-37 can regulate eicosanoid production in vivo, we used the acute peritonitis model Figure 6 . Cathelicidin regulates LTB 4 and TXB 2 production in vivo. A, B) WT male C57BL/6 mice were injected intraperitoneally with mCRAMP (mouse LL-37 othologue, 10 g/mouse, nϭ6), PBS (nϭ7), and mTNF␣ (50 ng/mouse, nϭ7) were used as negative and positive controls, respectively. C, D) mTNF␣ (50 ng/mouse) was injected intraperitoneally into WT (nϭ13) and Cnlp Ϫ/Ϫ (nϭ13) mice. After 4 h, the lavage fluid was collected, and cells and supernatants were separated by centrifugation at 400 g for 10 min. The cell pellets were resuspended in PBS, and the leukocyte composition was analyzed by FACS. The concentrations of LTB 4 (A, C) and TXB 2 (B, D) in supernatants were measured by EIA adjusted to number of macrophages. *P Ͻ 0.05, ***P Ͻ 0.001.
in the mouse in a dual approach. Thus, we injected murine cathelicidin (mCRAMP) into the peritoneal cavity of WT mice, which resulted in significantly increased levels of both LTB 4 and TXB 2 in the peritoneal lavage fluid. Conversely, injection of murine TNF-␣ into the peritoneal cavity of WT mice and mice deficient in mCRAMP (Cnlp Ϫ/Ϫ mice) revealed significantly reduced levels of LTB 4 and TXB 2 in lavage fluids from mCRAMP-deficient mice. We have previously shown that LL-37 also affects LTB 4 production from human neutrophils (21, 41) . Therefore, we cannot distinguish the cell source(s) of eicosanoid production in our mice experiments. Taken together, our in vivo results corroborate our in vitro results and provide convincing evidence that mCRAMP can regulate eicosanoid generation from leukocytes in vivo.
Pathophysiological implications of LL-37-induced eicosanoid production by HMDMs
An inflammatory response can be divided into separate phases, i.e., initiation, progression, and resolution, involving an array of cells and mediators. Recently, different classes of lipid mediators have been shown to promote discrete steps in this process, with LTB 4 as an early initiating mediator, followed by PGE 2 , and finally an array of proresolving lipid mediators, including lipoxins, resolvins, protectins, and maresins (42) . Levy et al. (43) demonstrated that during the course of a self-resolving acute inflammatory response there is a clear temporal staging and functional interconnections between distinct classes of eicosanoids. At early time points, 5-LOX-dependent LTB 4 generation prevails and contributes to the initiation phase. Then appears COX-derived PGE 2 , which dampens 5-LOX and promotes 15-LO expression and LXA 4 production, resulting in resolution. In our experimental setting, LTB 4 and TXA 2 production by LL-37-treated macrophages reached the highest levels at ϳ1 and 6 h, respectively. These temporal relationships suggest that LTB 4 will contribute to the initiation phase with recruitment of leukocytes to the inflammatory site, whereas TXA 2 will appear later during the progression phase with a role yet to be determined. We also observed that LL-37 induced PGE 2 formation, which in vivo may dampen the 5-LOX pathway and promote resolution (Fig. 1) .
Inasmuch as LL-37 and eicosanoids are both important mediators of the innate immune responses, the potential physiological or pathological consequences of LL-37-induced eicosanoid generation by macrophages are vast. If one considers the most predominant product downstream of LL-37, viz. TXA 2 , this prothrombotic mediator plays a role in endothelial migration and angiogenesis (44) and is an established atherogenic mediator (45) (46) (47) . Interestingly, elevated levels of both LL-37 and TXAS have been detected in human atherosclerotic plaque, associated with macrophages (23, 48, 49) , and mice deficient in the mouse cathelicidin mCRAMP are protected against atherosclerosis (50). Thus, it seems possible that macrophage-dependent LL-37-TXA 2 signaling may contribute to the pathogenesis of atherosclerosis and the thrombotic state characterizing plaque instability. Further studies are required to delineate the role of LL-37, TXA 2 , and LTB 4 in macrophage-driven disease processes, and whether this signaling pathway may offer opportunities for therapeutic interventions. HMDMs express high levels of P2X 7 R, cPLA 2 , 5-LOX, and COX-1 while COX-2 expression is hardly detected. B) Once HMDMs are exposed to LL-37, P2X 7 R is activated to induce calcium influx and rapid activation of ERK and p38 MAPKs, resulting in cPLA 2 phosphorylation and 5-LOX translocation from cytosol to the nuclear compartment. Activated cPLA 2 releases free AA, which is further metabolized into LTB 4 and TXB 2 in the early phase (ϳ1 h) via 5-LOX and COX-1, respectively. On the other hand, in the late phase, LL-37 is internalized by HMDMs which is associated with ERK MAPK activation, resulting in enhanced COX-2 expression and increased TXB 2 production.
